AGEN1571

News alerts, weekly reports and conference planners

Company:

Agenus

Drug class:

ILT-2 antagonist

‹

›

10ms

Study of AGEN1571 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=22, Completed, Agenus Inc. | Active, not recruiting --> Completed | Trial completion date: Jan 2027 --> Dec 2024 | Trial primary completion date: Jan 2027 --> Dec 2024

10 months ago

Trial completion • Trial completion date • Trial primary completion date

balstilimab (AGEN2034) • botensilimab (AGEN1181) • AGEN1571

almost2years

Study of AGEN1571 in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=22, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting | N=98 --> 22

almost 2 years ago

Enrollment closed • Enrollment change • Combination therapy • Metastases

balstilimab (AGEN2034) • botensilimab (AGEN1181) • AGEN1571

almost4years

AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses (AACR 2022)

AGEN1571 is a novel high-affinity ILT2 antagonist antibody that effectively antagonizes ILT2 to enhance T cell, NK cell, NKT cell, and myeloid activity. These data support clinical development of AGEN1571 as a therapeutic agent for patients with solid tumors.

almost 4 years ago

PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

CD4 expression

AGEN1571